Back to Journals » Cancer Management and Research » Volume 10

Celecoxib in breast cancer prevention and therapy

Authors Li J, Hao Q, Cao W, Vadgama JV, Wu Y

Received 28 June 2018

Accepted for publication 23 July 2018

Published 26 October 2018 Volume 2018:10 Pages 4653—4667

DOI https://doi.org/10.2147/CMAR.S178567

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Colin Mak

Peer reviewer comments 2

Editor who approved publication: Professor Raphael Catane


Jieqing Li,1,2 Qiongyu Hao,2 Wei Cao,2,3 Jaydutt V Vadgama,2,4,* Yong Wu2,4,*

1Department of Breast Surgery, Tianjin Central Hospital of Gynecology and Obstetrics, Tianjin, China; 2Division of Cancer Research and Training, Department of Internal Medicine, Charles R. Drew University of Medicine and Science, Los Angeles,CA, USA; 3Department of Nuclear Medicine, Union Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; 4David Geffen UCLA School of Medicine and UCLA Jonsson Comprehensive Cancer Center, University of California, Los Angeles, CA, USA

*These authors contributed equally to this work

Abstract:
Breast cancer has a high incidence worldwide. The results of substantial studis reveal that inflammation plays an important role in the initiation, development, and aggressiveness of many malignancies. The use of celecoxib, a novel NSAID, is repetitively associated with the reduced risk of the occurrence and progression of a number of types of cancer, particularly breast cancer. This observation is also substantiated by various meta-analyses. Clinical trials have been implemented on integration treatment of celecoxib and shown encouraging results. Celecoxib could be treated as a potential candidate for antitumor agent. There are, nonetheless, some unaddressed questions concerning the precise mechanism underlying the anticancer effect of celecoxib as well as its activity against different types of cancer. In this review, we discuss different mechanisms of anticancer effect of celecoxib as well as preclinical/clinical results signifying this beneficial effect.

Keywords:
celecoxib, breast cancer, COX-2, inflammation

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]